Hematopoietic growth factors - Use in normal blood and stem cell donors: Clinical and ethical issues. Summary of a conference

Transfusion

Volumn 48, Issue 9, 2008, Pages 2008-2025

  McCullough, Jeffrey ^a   Kahn, Jeffrey ^b   Adamson, John ^b   Anderlini, Paolo ^b   Benjamin, Richard ^b   Confer, Dennis ^b   Eapen, Mary ^b   Hirsch, Betsy ^b   Kuter, David ^b   Lazarus, Ellen ^b   Pamphilon, Derwood ^b   Stroncek, David ^b   Sugarman, Jeremy ^b   Wilson, Robert ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CORTICOSTEROID; DEXAMETHASONE; ELTROMBOPAG; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PEGYLATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PLERIXAFOR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT THROMBOPOIETIN; REMIPLISTIM; STROMAL CELL DERIVED FACTOR 1; THROMBOPOIETIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE HEART INFARCTION; ACUTE LUNG INJURY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANAPHYLAXIS; APHERESIS; ARTERIAL OXYGEN TENSION; ARTHRALGIA; BLOOD DONOR; BONE PAIN; CAPILLARY LEAK SYNDROME; CHROMOSOME ABERRATION; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GOUT; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INJECTION SITE ERYTHEMA; INSOMNIA; IRITIS; KERATITIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG INFILTRATE; MALAISE; MEDICAL ETHICS; MONOSOMY 7; MONOTHERAPY; NAUSEA; PAIN; PARESTHESIA; PERIORAL PARESTHESIA; POTASSIUM BLOOD LEVEL; RISK BENEFIT ANALYSIS; SICKLE CELL CRISIS; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; SPLEEN RUPTURE; SPLEEN SIZE; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; STROKE; SUBCAPSULAR CATARACT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOSIS; TREATMENT INDICATION; VASCULITIS;

BLOOD DONORS; BLOOD TRANSFUSION; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS;

EID: 51049108550     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01788.x     Document Type: Conference Paper

References (135)

1. Hartung T, Docke WD, Gantner F, Krieger G, Sauer A, Stevens P, Volk H-D, Wendel A. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995 85 : 2482 9.
2. Pollmächer T, Korth C, Mullington J, Schreiber W, Sauer J, Vedder H, Galanos C, Holsboer F. Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood 1996 87 : 900 5.
3. Kitabayashi A, Hirokawa M, Hatano Y, Lee M, Kuroki J, Niitsu H, Miura AB. Granulocyte colony-stimulating factor downregulates allogeneic immune responses by posttranscriptional inhibition of tumor necrosis factor-alpha production. Blood 1995 86 : 2220 7.
4. Weiss M, Moldawer LL, Schneider EM. Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Blood 1999 93 : 425 39.
5. Ohsaka A, Saionji K, Kuwaki T, Takeshima T, Igari J. Granulocyte colony-stimulating factor administration modulates the surface expression of effector cell molecules on human monocytes. Br J Haematol 1995 89 : 465 72.
6. Kuroiwa M, Okamura T, Kanaji T, Okamura S, Harada M, Niho Y. Effects of granulocyte colony-stimulating factor on the hemostatic system in healthy volunteers. Int J Hematol 1996 63 : 311 6.
7. Shimoda K, Okamura S, Harada N, Kondo S, Okamura T, Niho Y. Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest 1993 91 : 1310 3.
8. Franzke A, Piao W, Lauber J, Gatzlaff P, Könecke C, Hansen W, Schmitt-Thomsen A, Hertenstein B, Buer J, Ganser A. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. Blood 2003 102 : 734 9.
9. Klangsinsirikul P, Russell NH. Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. Exp Hematol 2002 30 : 495 501.
10. Rutella S, Zavala F, Danese S, Kared H, Leone G. Granulocyte colony-stimulating factor: a novel mediator of T-cell tolerance. J Immunol 2005 175 : 7085 91.
11. Karawajczyk M, Hoglund M, Ericsson J, Venge P. Administration of G-CSF to healthy subjects: the effects on eosinophil counts and mobilization of eosinophil granule proteins. Br J Haematol 1997 96 : 259 65.
12. Hakansson L, Hoglund M, Jonsson UB, Torsteinsdottir I, Xu X, Venge P. Effects of in vivo administration of G-CSF on neutrophil and eosinophil adhesion. Br J Haematol 1997 98 : 603 11.
13. Lassailly F, Sielleur I, Blaise D, Chabannon C. rhG-CSF does not affect the phenotype of adult donor peripheral blood NK cells. Bone Marrow Transplant 2005 35 : 25 32.
14. Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 1996 88 : 335 40.
15. Chatta GS, Price TH, Allen RC, Dale DC. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994 84 : 2923 9.
16. de Haas M, Kerst JM, van der Schoot CE, Calafat J, Hack CE, Nuijens JH, Roos D, van Oers RH, von dem Borne AE. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effects on circulating neutrophils. Blood 1994 84 : 3885 94.
17. Roilides E, Walsh TJ, Pizzo PA, Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991 163 : 579 83.
18. Falanga A, Marchetti M, Evangelista V, Manarini S, Oldani E, Giovanelli S, Galbusera M, Cerletti C, Barbui T. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 1999 93 : 2506 14.
19. Hakansson L, Hoglund M, Jonsson UB, Torsteinsdottir I, Xu X, Venge P. Effects of in vivo administration of G-CSF on neutrophil and eosinophil adhesion. Br J Haematol 1997 98 : 603 11.
20. Grigg AP, Roberts AW, Raunow H, Houghton S, Layton JE, Boyd AW, McGrath KM, Maher D. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995 86 : 4437 45.
21. Link H, Arseniev L, Bahre O, Berenson RJ, Battmer K, Kadar JG, Jacobs R, Casper J, Kühl J, Schubert J, Diedrich H, Poliwoda H. Combined transplantation of allogeneic bone marrow and CD34+ blood cells. Blood 1995 86 : 2500 8.
22. Stroncek DF, Clay ME, Petzoldt ML, Smith J, Jaszcz W, Oldham FB, McCullough J. Treatment of normal individuals with granulocyte-colony- stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion 1996 36 : 601 10.
23. Korbling M, Huh YO, Durett A, Mirza N, Miller P, Engel H, Anderlini P, van Besien K, Andreeff M, Przepiorka D, Deisseroth AB, Champlin RE. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995 86 : 2842 8.
24. Anderlini P, Przepiorka D, Seong C, Smith TL, Huh YO, Lauppe J, Champlin R, Körbling M. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 1997 37 : 507 12.
25. Matsunaga T, Sakamaki S, Kohgo Y, Ohi S, Hirayama Y, Niitsu Y. Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation. Bone Marrow Transplant 1993 11 : 103 8.
26. Tjonnfjord GE, Steen R, Evensen SA, Thorsby E, Egeland T. Characterization of CD34+ peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1994 84 : 2795 801.
27. Liu F, Poursine-Laurent J, Link DC. Expression of the G-CSF receptor on hematopoietic progenitor cells is not required for their mobilization by G-CSF. Blood 2000 95 : 3025 31.
28. Körbling M, Reuben JM, Gao H, Lee BN, Harris DM, Cogdell D, Giralt SA, Khouri IF, Saliba RM, Champlin RE, Zhang W, Estrov Z. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion 2006 46 : 1795 802.
29. Semerad CL, Christopher MJ, Liu F, Short B, Simmons PJ, Winkler I, Levesque JP, Chappel J, Ross FP, Link DC. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005 106 : 3020 7.
30. Takamatsu Y, Simmons PJ, Moore RJ, Morris HA, To LB, Lévesque J-P. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood 1998 92 : 3465 73.
31. Fujii K, Ishimaru F, Kozuka T, Matsuo K, Nakase K, Kataoka I, Tabayashi T, Shinagawa K, Ikeda K, Harada M, Tanimoto M. Elevation of serum hepatocyte growth factor during granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization. Br J Haematol 2004 124 : 190 4.
32. Stroncek DF, Clay ME, Petzoldt ML, Smith J, Jaszcz W, Oldham FB, Mccullough J. Treatment of normal individuals with granulocyte-colony- stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion 1996 36 : 601 10.
33. Platzbecker U, Prange-Krex G, Bornhauser M, Koch R, Soucek S, Aikele P, Haack A, Haag C, Schuler U, Berndt A, Rutt C, Ehninger G, Hölig K. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 2001 41 : 184 9.
34. Stroncek DF, Dittmar K, Shawker T, Heatherman A, Leitman SF. Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF. J Transl Med 2004 2 : 25.
35. Stroncek D, Shawker T, Follmann D, Leitman SF. G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003 43 : 609 13.
36. Becker PS, Wagle M, Matous S, Swanson RS, Pihan G, Lowry PA, Stewart FM, Heard SO. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997 3 : 45 9. Erratum in: Biol Blood Marrow Transplant 1997 Jun;3(2):108.
37. Brown SL, Dale DC. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997 3 : 341 3.
38. Falzetti F, Aversa F, Minelli O, Tabilio A. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999 353 : 555.
39. Dincer AP, Gottschall J, Margolis DA. Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. J Pediatr Hematol Oncol 2004 26 : 761 3.
40. Nuamah NM, Goker H, Kilic YA, Dagmoura H, Cakmak A. Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (G-CSF). A case report and review of the literature. Haematologica 2006 91 5 Suppl : ECR08.
41. Adler BK, Salzman DE, Carabasi MH, Vaughan WP, Reddy VV, Prchal JT. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 2001 97 : 3313 4.
42. Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. Lancet 1998 351 : 959.
43. Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. Blood 2001 97 : 3998 9.
44. Kang EM, Areman EM, David-Ocampo V, Fitzhugh C, Link ME, Read EJ, Leitman SF, Rodgers GP, Tisdale JF. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 2002 99 : 850 5.
45. Arimura K, Inoue H, Kukita T, Matsushita K, Akimot M, Kawamata N, Yamaguchi A, Kawada H, Ozak A, Arima N, Te C. Acute lung injury in a healthy donor during mobilization of peripheral blood stem cells using granulocyte-colony stimulating factor alone. Haematologica 2005 90 : ECR10.
46. Gertz MA, Lacy MQ, Bjornsson J, Litzow MR. Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor-induced pulmonary toxicity. J Hematother Stem Cell Res 2000 9 : 635 43.
47. Yoshida I, Matsuo K, Teshima T, Hashimoto D, Tanimoto Y, Harada M, Tanimoto M. Transient respiratory disturbance by granulocyte-colony-stimulating factor administration in healthy donors of allogeneic peripheral blood progenitor cell transplantation. Transfusion 2006 46 : 186 92.
48. Liles WC, Huang JE, Llewellyn C, SenGupta D, Price TH, Dale DC. A comparative trial of granulocyte-colony-stimulating factor and dexamethasone, separately and in combination, for the mobilization of neutrophils in the peripheral blood of normal volunteers. Transfusion 1997 37 : 182 7.
49. Stroncek DF, Yau YY, Oblitas J, Leitman SF. Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. Transfusion 2001 41 : 1037 44.
50. McCullough J, Clay M, Herr G, Smith J, Stroncek D. Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors. Transfusion 1999 39 : 1136 40.
51. Ghodsi Z, Strauss RG. Cataracts in neutrophil donors stimulated with adrenal corticosteroids. Transfusion 2001 41 : 1464 8.
52. Burch JW, Mair DC, Meny GM, Moroff G, Ching SS, Naidoff MA, Steuer ER, Loftus SA, Armstrong J, Clemons TE, Klein BE. The risk of posterior subcapsular cataracts in granulocyte donors. Transfusion 2005 45 : 1701 8.
53. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, Sutherland W, Stoney G, Kern B, Fletcher FA, Cohen A, Korach E, Ulich T, McNiece I, Lockbaum P, Miller-Messana MA, Gardner S, Hunt T, Schwab G. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999 27 : 1724 34.
54. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005 106 : 1867 74.
55. Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K, Calandra G, Christensen J, Wood B, Price TH, Dale DC. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005 45 : 295 300.
56. Larochelle A, Krouse A, Metzger M, Orlic D, Donahue RE, Fricker S, Bridger G, Dunbar CE, Hematti P. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006 107 : 3772 8.
57. Burroughs L, Mielcarek M, Little MT, Bridger G, Macfarland R, Fricker S, Labrecque J, Sandmaier BM, Storb R. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 2005 106 : 4002 8.
58. Nervi B, Link DC, Dipersio JF. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 2006 99 : 690 705.
59. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hübel K, Cooper S, Hangoc G, Bridger GJ, Henson GW, Calandra G, Dale DC. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003 102 : 2728 30.
60. Leone AM, Rutella S, Bonanno G, Contemi AM, de Ritis DG, Giannico MB, Rebuzzi AG, Leone G, Crea F. Endogenous G-CSF and CD34+ cell mobilization after acute myocardial infarction. Int J Cardiol 2006 111 : 202 8.
61. Wojakowski W, Tendera M, Michalowska A, Majka M, Kucia M, Maślankiewicz K, Wyderka R, Ochała A, Ratajczak MZ. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 2004 110 : 3213 20.
62. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki S, Shimada T, Oike Y, Imaizumi T. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001 103 : 2776 9.
63. Ince H, Petzsch M, Kleine HD, Eckard H, Rehders T, Burska D, Kische S, Freund M, Nienaber CA. Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI). Trial Circulation 2005 112 9 Suppl : I73 80.
64. Ripa RS, Jørgensen E, Wang Y, Thune JJ, Nilsson JC, Sondergaard L, Johnsen HE, Kober L, Grande P, Kastrup J. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial. Circulation 2006 113 : 1983 92.
65. Zohlnhöfer D, Ott I, Mehilli J, Schömig K, Michalk F, Ibrahim T, Meisetschläger G, von Wedel J, Bollwein H, Seyfarth M, Dirschinger J, Schmitt C, Schwaiger M, Kastrati A, Schömig A REVIVAL-2 Investigators. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 2006 295 : 1003 10.
66. Engelmann MG, Theiss HD, Hennig-Theiss C, Huber A, Wintersperger BJ, Werle-Ruedinger AE, Schoenberg SO, Steinbeck G, Franz WM. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J Am Coll Cardiol 2006 48 : 1712 21.
67. Hill JM, Syed MA, Arai AE, Powell TM, Paul JD, Zalos G, Read EJ, Khuu HM, Leitman SF, Horne M, Csako G, Dunbar CE, Waclawiw MA, Cannon RO III. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol 2005 46 : 1643 8.
68. Joseph J, Rimawi A, Mehta P, Cottler-Fox M, Sinha A, Singh BK, Pacheco R, Smith ES 3rd., Mehta JL. Safety and effectiveness of granulocyte-colony stimulating factor in mobilizing stem cells and improving cytokine profile in advanced chronic heart failure. J Am Coll Cardiol 2006 97 : 681 4.
69. Hüttmann A, Dührsen U, Stypmann J, Noppeney R, Nückel H, Neumann T, Gutersohn A, Nikol S, Erbel R. Granulocyte colony-stimulating factor-induced blood stem cell mobilisation in patients with chronic heart failure - feasibility, safety and effects on exercise tolerance and cardiac function. Basic Res Cardiol 2006 101 : 78 86.
70. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, Kaneko T, Takano T, Ikuta K, Tsukimoto I Japan Childhood Aplastic Anemia Study Group. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002 100 : 786 90.
71. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003 21 : 1195 204.
72. Makita K, Ohta K, Mugitani A, Hagihara K, Ohta T, Yamane T, Hino M. Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004 33 : 661 5.
73. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Vose JM, Bierman PJ, Kuter DJ, Trifilio SM, Devine SM, Tallman MS. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006 135 : 642 50.
74. Sloand EM, Yong AS, Ramkissoon S, Solomou E, Bruno TC, Kim S, Fuhrer M, Kajigaya S, Barrett AJ, Young NS. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A 2006 103 : 14483 8.
75. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004 32 : 122 30.
76. Kaplinsky C, Trakhtenbrot L, Hardan I, Reichart M, Daniely M, Toren A, Amariglio N, Rechavi G, Izraeli S. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003 32 : 31 4.
77. Pamphilon D, Mackinnon S, Nacheva E, Russell N, Wilson K, Clay M, Miller J, Green A, Navarrete C, Contreras M. The use of granulocyte colony-stimulating factor in volunteer blood and marrow registry donors. Bone Marrow Transplant 2006 38 : 699 700 letter P, Chan FA, Champlin RE, Körbling M, Strom SS. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant 2002 30 : 661 3.
78. Freedman MH. Safety of long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia. Curr Opin Hematol 1997 4 : 217 24.
79. Hasenclever D, Sextro M. Safety of alloPBPCT donors: biometrical considerations on monitoring long-term risks. Bone Marrow Transplant 1996 17 : S28 30.
80. Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, Menchaca D, Tomita D, Ozer H, Harker L. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997 336 : 404 9.
81. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, Broxmeyer HE, Kudelkà AP, Freedman RS, Edwards CL, Gershenson D, Jones D, Ashby M, Kavanagh JJ. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000 132 : 364 8.
82. Nomura S, Dan K, Hotta T, Fujimura K, Ikeda Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002 100 : 728 30.
83. Somlo G, Sniecinski I, ter Veer A, Longmate J, Knutson G, Vuk-Pavlovic S, Bhatia R, Chow W, Leong L, Morgan R, Margolin K, Raschko J, Shibata S, Tetef M, Yen Y, Forman S, Jones D, Ashby M, Fyfe G, Hellmann S, Doroshow JH. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood 1999 93 : 2798 806.
84. Piacibello W, Sanavio F, Garetto L, Severino A, Bergandi D, Ferrario J, Fagioli F, Berger M, Aglietta M. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997 89 : 2644 53.
85. Sullivan MT, Cotton R, Read EJ, Wallace EL. Blood collection and transfusion in the United States in 2001. Transfusion 2007 47 : 385 94.
86. Kuter DJ. The use of PEG-rhuMGDF in platelet apheresis. Stem Cells 1998 16 Suppl 2 : 231 42.
87. Kuter DJ, Goodnough LT, Romo J, DiPersio J, Peterson R, Tomita D, Sheridan W, McCullough J. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001 98 : 1339 45.
88. Goodnough LT, Kuter DJ, McCullough J, Slichter SJ, DiPersio J, Romo J, Peterson R, Smith KJ, Raife T, Tomita D, Armstrong S. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood 2001 98 : 1346 51.
89. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001 98 : 3241 8.
90. Cerneus D, Brown K, Harris R, End D, Molloy C, Yurkow E, Koblish H, Franks C, Moolenaar M, Burggraaf K. Stimulation of platelet production in healthy volunteers by a novel pegylated peptide-based thrombopoietin (TPO) receptor agonist [abstract Blood 2005 106 : 363a, abstract B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004 76 : 628 38.
91. Erickson-Miller CL, DeLorme E, Tian SS, Hopson CB, Stark K, Giampa L, Valoret EI, Duffy KJ, Luengo JL, Rosen J, Miller SG, Dillon SB, Lamb P. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005 33 : 85 93.
92. Jenkins J, Nicholl R, Williams D, Baidoo C, Phillips J, Deng Y, Kitchen V, Erickson-Miller C. An oral, non-peptide, small molecule thrombopoietin receptor agonist increases platelet counts in healthy subjects [abstract Blood 2004 104 : 797a, abstract RE, Tempel DL, Lucek R, Kuter DJ. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers [abstract Blood 2006 108 : 145a, abstract T, Tsunoda H, Yabuta N, Nakano K, Yoshino T, Hirata Y, Ohtomo T, Nezu J, Sakumoto H, Ono K, Saito M, Kumagai E, Nanami M, Kaneko A, Yoshikubo T, Tsuchiya M. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood 2005 105 : 562 6.
93. Kai M, Motoki K, Yoshida H, Emuta C, Chisaka Y, Tsuruhata K, Endo C, Muto M, Shimabe M, Nishiyama U, Hagiwara T, Matsumoto A, Miyazaki H, Kataoka S. Domain subclass conversion improved activity of anti-Mpl agonist antibodies in the form of whole IgG [abstract Blood 2006 108 : 336a, abstract JB, Cheng G, Saleh M, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. Analysis of bleeding in patients with immune thrombocytopenic purpura (ITP): a randomized, double-blind, placebo-controlled trial of eltrombopag, an oral platelet growth factor [abstract Blood 2006 108 : 144a, abstract JB, Kuter DJ, George LN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006 355 : 1672 81.
94. Kuter D, Bussel J, George J, Aledort L, Lichtin A, Lyons R, Nieva J, Wasser J, Bourgeois E, Kappers-Klunne M, Lefrere F, Schipperus M, Kelly R, Christal J, Guo M, Nichol J. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update [abstract Blood 2006 108 : 144a, abstract JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH TPL102357 Study Group. Eltrombopag for thrombocytopenic in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007 357 : 2227 36.
95. Spivak JL. Recombinant human erythropoietin and its role in transfusion medicine. Transfusion 1994 34 : 1 4.
96. Fullerton DA, Campbell DN, Whitman GJ. Use of human recombinant erythropoietin to correct severe preoperative anemia. Ann Thorac Surg 1991 51 : 825 6.
97. Gaudiani VA, Mason HD. Preoperative erythropoietin in Jehovah's Witnesses who require cardiac procedures. Ann Thorac Surg 1991 41 : 823 4.
98. Shi PA, Ness PM. Two-unit red cell apheresis and its potential advantages over traditional whole blood donation: a review. Transfusion 1999 39 : 218 25.
99. Bahlmann FH, Groot K, Spandau J-M, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D. Erythropoietin regulates endothelial progenitor cells. Blood 2004 103 : 921 6.
100. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 1994 91 : 3974 8.
101. Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. Eur J Clin Invest 2003 33 : 891 6.
102. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005 353 : 782 92.
103. Eschbach JW. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III, multicenter clinical trial. Ann Intern Med, 1989 111 : 992 1000.
104. Besarab A. The effects of normal as compared with low hematocrit values in patients with cardiac-disease who are receiving hemodialysis and epoetin. N Engl J Med 1998 339 : 584 90.
105. Singh AK. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006 355 : 2084 98.
106. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003 362 : 1255 60.
107. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005 23 : 5960 72.
108. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007 25 : 1027 32.
109. Newman BH. Blood donor complications after whole-blood donation. Curr Opin Hematol 2004 11 : 339 45.
110. Eder AF, Dy BA, Kennedy J, Notari E, Benjamin RJ. Donor complications during automated plateletpheresis procedures compared to whole blood collection. J Clin Apheresis 2007 22 : 53 abstract SF, Boltansky H, Alter HJ, Pearson FC, Kaliner MA. Allergic reactions in healthy plateletpheresis donors caused by sensitization to ethylene oxide gas. N Engl J Med 1986 315 : 1192 6.
111. Buchta C Bittner C, Höcker P, Macher M, Schmid R, Seger C, Dettke M. Donor exposure to the plasticizer di(2-ethylhexyl)phthalate during plateletpheresis. Transfusion 2003 43 : 1115 20.
112. Buchta C, Dettke M. The above letter was sent to Buchta et al.; Drs Buchta and Dettke offered the following reply. Transfusion 2006 46 : 1459 60.
113. Bolan CD, Cecco SA, Yau YY, Wesley RA, Oblitas JM, Rehak NN, Leitman SF. Randomized placebo-controlled study of oral calcium carbonate supplementation in plateletpheresis: II. Metab Eff 2003 43 : 1414 22.
114. Bolan CD, Greer SE, Cecco SA, Oblitas JM, Rehak NN, Leitman SF. Comprehensive analysis of citrate effects during plateletpheresis in normal donors. Transfusion 2001 41 : 1165 71.
115. Lasky LC, Lin A, Kahn RA, McCullough J. Donor platelet response and product quality assurance in plateletpheresis. Transfusion 1981 21 : 247 60.
116. Weisbach V, Friedlein H, Glaser A, Zingsem J, Zimmermann R, Eckstein R. The influence of automated plateletpheresis on systemic levels of hematopoietic growth factors. Transfusion 1999 39 : 889 94.
117. Dettke M, Hlousek M, Kurz M, Leitner G, Rosskopf K, Stiegler G, Stohlawetz P, Worel N, Höcker P, Panzer S. Increase in endogenous thrombopoietin in healthy donors after automated plateletpheresis. Transfusion 1998 38 : 449 53.
118. Gyongyossy-Issa MI, Miranda J, Devine DV. Generation of reticulated platelets in response to whole blood donation or plateletpheresis. Transfusion 2001 41 : 1234 40.
119. Stohlawetz P, Stiegler G, Jilma B, Dettke M, Hocker P, Panzer S. Measurement of the levels of reticulated platelets after plateletpheresis to monitor activity of thrombopoiesis. Transfusion 1998 38 : 454 8.
120. Wagner T, Schwartz DW, Winter M, Kabrna E, Kollars M, Schwarzinger I, Lanzer G, Mayr WR, Geissler K. Kinetics of CFU-Mk after automated plateletpheresis. Vox Sang 2001 81 : 167 71.
121. Strauss RG. Effects on donors of repeated leukocyte losses during plateletpheresis. J Clin Apheresis 1994 9 : 130 4.
122. Lazarus EF, Browning J, Norman J, Oblitas J, Leitman SF. Sustained decreases in platelet count associated with multiple, regular plateletpheresis donations. Transfusion 2001 41 : 756 61.
123. Katz LM, Palmer K, McDonnell E. Restrictions on the annual number of platelet products from plateletpheresis (P) donors in 2005 FDA draft guidance are not necessary [abstract Transfusion 2006 46 9S : 1a, abstract #P1-030A.
124. Vassallo RR, Murphy S Notari EP. Changes in donor platelet counts with repeated plateletpheresis procedures [abstract Transfusion 2006 46 9S : 5a, abstract #S8-030C.
125. Richa E, Krueger P, Burgstaler EA, Bryant SC, Winters JL. The effect of double and triple apheresis PLT product donation on apheresis donor PLT and WBC counts [abstract Transfusion 2006 46 9S : 39a, abstract #SP2.
126. Ghodsi Z, Strauss RG. Cataracts in neutrophil donors stimulated with adrenal corticosteroids. Transfusion 2001 41 : 1464 8.
127. Burch JW, Mair DC, Meny GM, Moroff G, Ching SS, Naidoff MA, Steuer ER, Loftus SA, Armstrong J, Clemons TE, Klein BE. The risk of posterior subcapsular cataracts in granulocyte donors. Transfusion 2005 45 : 1701 8.
128. Beal R. The international society of blood transfusion and a code of ethics for blood donation and transfusion (2000). Vox Sang 2002 82 : 165 6.
129. De Silvestro G, Marson P, Cesaro S, Messina C. Legislative and ethical aspects of administering granulocyte colony-stimulating factor to normal donors. Haematologica 2002 87 8 Suppl : 28 34.
130. Volk EE, Domen RE, Smith ML. An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor. Arch Pathol Lab Med 1999 23 : 508 13.
131. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont report: ethical principles and guidelines for the protection of human subjects of research. [The Belmont Report April 18, 1979. Available from http://www.hhs.gov/ohrp/humansubjects/guidance/ belmont.htm
132. Switzer GE, Dew MA, Butterworth VA, Simmons RG, Schimmel M. Understanding donors' motivations: a study of unrelated bone marrow donors. Soc Sci Med 1997 45 : 137 47.
133. Matas AJ. Garvey CA. Jacobs CL. Kahn JP. Nondirected donation of kidneys from living donors. N Engl J Med 2002 343 : 433 6.
134. Appelbaum PS, Lidz CW, Grisso T. Therapeutic misconception in clinical research: frequency and risk factors. IRB 2004 26 : 1 8.
135. Guidance for industry: adverse reactions section of labeling for human prescription drug and biological products - content and format. [PDF version Rockville, MD: Food and Drug Administration; January 18, 2006. Available from http://www.fda.gov/cber/gdlns/cfadvers.htm